CIC bioGUNE researcher Ana Ruiz Sáenz receives award for a project aimed at advancing personalised treatment for metastatic breast cancer

Bizkaia, News

The initiative, coordinated by CIC bioGUNE, has been recognised in the tenth edition of the AstraZeneca Foundation Young Researchers Awards, in the Oncology, Precision Medicine and Immuno-oncology category

The research will analyse how differential glycosylation patterns influence the effectiveness of trastuzumab deruxtecan treatment in patients with metastatic breast cancer

Ana Ruiz Sáenz, a researcher at CIC bioGUNE, a member of BRTA, has received an award in the tenth edition of the AstraZeneca Foundation Young Researchers Awards for a research project focused on metastatic breast cancer. The initiative has been recognised in the Oncology, Precision Medicine and Immuno-oncology category and will receive €225,000 in funding.

The project, entitled “Differential glycosylation in metastatic breast cancer as a modulator of trastuzumab deruxtecan efficacy”, aims to analyse how differential glycosylation patterns influence and modulate the effectiveness of trastuzumab deruxtecan treatment in metastatic breast cancer, opening up new avenues for optimising personalised therapeutic responses in these patients.

The research is coordinated by Ana Ruiz Sáenz, an Ikerbasque Research Professor and head of the Cancer Therapy Resistance Group at CIC bioGUNE. It also involves Toni Celià-Terrassa, from the Hospital del Mar Research Institute (Catalonia), and Natalia Reglero Real, from the Severo Ochoa Molecular Biology Centre (CBMSO, CSIC-UAM), in the Community of Madrid. The initiative is also supported by the patient association Con Cáncer Y Con Metas.

Recognition of collaborative biomedical research

The project led by Ana Ruiz Sáenz is one of four research initiatives recognised in the tenth edition of the AstraZeneca Foundation Young Researchers Awards. These awards aim to promote research among groups of young scientists from different Spanish autonomous communities who collaborate on network-based research projects to generate results that can ultimately benefit the wider population.

The awards have recognised four projects in the following areas: Cardiovascular, Renal and Metabolism; Oncology, Precision Medicine and Immuno-oncology; Respiratory and Immunology; and Infectious and Vaccine-preventable Diseases. Each project will receive €225,000 to carry out clinical and translational research through collaboration between centres in different autonomous communities.

Held under the motto “Science is written with commitment”, this tenth edition coincided with the 25th anniversary of the AstraZeneca Foundation and achieved a record level of participation, with 51 projects submitted and 189 research groups involved from 16 autonomous communities. More than 70% of the proposals were led by women.

Applications were evaluated by the Carlos III Health Institute (ISCIII), which was responsible for ensuring the rigour and independence of the assessment process.

Over the course of its ten editions, the AstraZeneca Foundation has allocated €5.2 million to these awards, supporting more than 100 emerging researchers and mobilising nearly 700 scientific research groups across Spain.

Share

Other news

Menarini’s incorporation as a Business Partner strengthens the connection between the biopharmaceutical industry and the Basque Country’s business, scientific and healthcare ecosystem, opening up new opportunities for collaboration

Bizkaia, News

Learn more aboutMenarini’s incorporation as a Business Partner strengthens the connection between the biopharmaceutical industry and the Basque Country’s business, scientific and healthcare ecosystem, opening up new opportunities for collaboration